{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:09:38Z","timestamp":1780499378963,"version":"3.54.1"},"posted":{"date-parts":[[2026,6,3]]},"group-title":"In Review","reference-count":71,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,5,11]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  Noninvasive quantification of immune markers such as programmed death ligand-1 (PD-L1) remains a major challenge because conventional molecular imaging methods cannot readily distinguish target-bound from nonspecifically retained probes within the tumor microenvironment. Here, we establish a framework for noninvasive quantification of PD-L1 expression in deep-seated hepatocellular carcinoma (HCC) using asymptotic time-domain (ATD) fluorescence lifetime tomography.\n                  <italic>In vivo<\/italic>\n                  time-domain fluorescence imaging was performed in mice bearing orthotopic HCC tumors following administration of a PD-L1-targeted near-infrared fluorescent probe (\u03b1PDL1-800). Multi-exponential analysis of time-domain fluorescence data was used to derive four amplitude-based metrics of PD-L1 expression. Quantitative\n                  <italic>in vivo<\/italic>\n                  measurements obtained from ATD tomography were validated against\n                  <italic>ex vivo<\/italic>\n                  PD-L1 expression measured by Western blotting. Among the evaluated metrics, a normalized parameter that accounts for inter-lifetime crosstalk demonstrated the strongest correlation with\n                  <italic>ex vivo<\/italic>\n                  PD-L1 expression (r\n                  <sup>2<\/sup>\n                  \u2009=\u20090.77). These findings establish a foundation for a noninvasive, nonionizing imaging approach to quantify and monitor receptor expression and support a future path for the longitudinal assessment of immune biomarkers in both preclinical studies and clinical settings.\n                <\/p>","DOI":"10.21203\/rs.3.rs-9682833\/v1","type":"posted-content","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:15:34Z","timestamp":1780496134000},"source":"Crossref","is-referenced-by-count":0,"title":["Whole-body tomographic fluorescence lifetime imaging of PD-L1 expression"],"prefix":"10.21203","author":[{"given":"Rahul","family":"Pal","sequence":"first","affiliation":[{"name":"Massachusetts Eye and Ear Infirmary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Krishnamoorthy","sequence":"additional","affiliation":[{"name":"Indian Institute of Technology Madras"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Morita","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuyo","family":"Morita","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asemare M.","family":"Taddese","sequence":"additional","affiliation":[{"name":"Massachusetts Eye and Ear Infirmary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan G.","family":"Duda","sequence":"additional","affiliation":[{"name":"Houston Methodist"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand T.N.","family":"Kumar","sequence":"additional","affiliation":[{"name":"Massachusetts Eye and Ear Infirmary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer JR","year":"2012","unstructured":"Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366, 2455\u20132465, doi:10.1056\/NEJMoa1200694 (2012).","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian SL","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366, 2443\u20132454, doi:10.1056\/NEJMoa1200690 (2012).","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad G","year":"2021","unstructured":"Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184, 5309\u20135337, doi:10.1016\/j.cell.2021.09.020 (2021).","journal-title":"Cell"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12040764","author":"Guo Z","year":"2024","unstructured":"Guo, Z., Yu, J., Chen, Z., Chen, S. & Wang, L. Immunological Mechanisms behind Anti-PD-1\/PD-L1 Immune Checkpoint Blockade: Intratumoral Reinvigoration or Systemic Induction? Biomedicines 12, doi:10.3390\/biomedicines12040764 (2024)."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry AB","year":"2017","unstructured":"El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389, 2492\u20132502, doi:10.1016\/S0140-6736(17)31046-2 (2017).","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst RS","year":"2014","unstructured":"Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563\u2013567, doi:10.1038\/nature14011 (2014).","journal-title":"Nature"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","article-title":"PD-1\/PD-L1 inhibitors","volume":"23","author":"Sunshine J","year":"2015","unstructured":"Sunshine, J. & Taube, J. M. PD-1\/PD-L1 inhibitors. Curr Opin Pharmacol 23, 32\u201338, doi:10.1016\/j.coph.2015.05.011 (2015).","journal-title":"Curr Opin Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin X","year":"2024","unstructured":"Lin, X. et al. Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer 23, 108, doi:10.1186\/s12943-024-02023-w (2024).","journal-title":"Mol Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/biom13081209","article-title":"Current Landscape and Future Direction of PD-1\/PD-L1 Checkpoint Inhibitors in Cancer Treatment","volume":"13","author":"Serrati S","year":"2023","unstructured":"Serrati, S. & Margheri, F. Current Landscape and Future Direction of PD-1\/PD-L1 Checkpoint Inhibitors in Cancer Treatment. Biomolecules 13, doi:10.3390\/biom13081209 (2023).","journal-title":"Biomolecules"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002794add1","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma","volume":"11","author":"Addendum 1","year":"2023","unstructured":"Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer 11, doi:10.1136\/jitc-2021-002794add1 (2023).","journal-title":"J Immunother Cancer"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma","volume":"1","author":"Abou-Alfa GK","year":"2022","unstructured":"Abou-Alfa, G. K. et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid 1, EVIDoa2100070, doi:10.1056\/EVIDoa2100070 (2022).","journal-title":"NEJM Evid"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf286","article-title":"First-line atezolizumab\/bevacizumab or durvalumab\/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study","volume":"30","author":"Kournoutas I","year":"2025","unstructured":"Kournoutas, I. et al. First-line atezolizumab\/bevacizumab or durvalumab\/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study. Oncologist 30, doi:10.1093\/oncolo\/oyaf286 (2025).","journal-title":"Oncologist"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41416-024-02684-w","article-title":"The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications","volume":"131","author":"Chen K","year":"2024","unstructured":"Chen, K., Shuen, T. W. H. & Chow, P. K. H. The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications. British Journal of Cancer 131, 420\u2013429, doi:10.1038\/s41416-024-02684-w (2024).","journal-title":"British Journal of Cancer"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"189334","DOI":"10.1016\/j.bbcan.2025.189334","article-title":"PD-1\/PD-L1 blockade therapy in hepatocellular carcinoma: Current status and potential biomarkers","volume":"1880","author":"Xu P","year":"2025","unstructured":"Xu, P., Hong, C., Liu, L. & Xiao, L. PD-1\/PD-L1 blockade therapy in hepatocellular carcinoma: Current status and potential biomarkers. Biochim Biophys Acta Rev Cancer 1880, 189334, doi:10.1016\/j.bbcan.2025.189334 (2025).","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40164-024-00539-x","article-title":"Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside","volume":"13","author":"Yin Y","year":"2024","unstructured":"Yin, Y. et al. Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside. Experimental Hematology & Oncology 13, 72, doi:10.1186\/s40164-024-00539-x (2024).","journal-title":"Experimental Hematology & Oncology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3892\/etm.2023.12285","article-title":"Current state and challenges of emerging biomarkers for immunotherapy in hepatocellular carcinoma (Review)","volume":"26","author":"Cheng M","year":"2023","unstructured":"Cheng, M., Zheng, X., Wei, J. & Liu, M. Current state and challenges of emerging biomarkers for immunotherapy in hepatocellular carcinoma (Review). Exp Ther Med 26, 586, doi:10.3892\/etm.2023.12285 (2023).","journal-title":"Exp Ther Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1125905","DOI":"10.3389\/fimmu.2023.1125905","article-title":"Mechanistic rationales for combining immunotherapy with radiotherapy","volume":"14","author":"Chi A","year":"2023","unstructured":"Chi, A. & Nguyen, N. P. Mechanistic rationales for combining immunotherapy with radiotherapy. Front Immunol 14, 1125905, doi:10.3389\/fimmu.2023.1125905 (2023).","journal-title":"Front Immunol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00262-018-2275-0","article-title":"Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers","volume":"68","author":"Chiang SF","year":"2019","unstructured":"Chiang, S. F. et al. Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers. Cancer Immunol Immunother 68, 283\u2013296, doi:10.1007\/s00262-018-2275-0 (2019).","journal-title":"Cancer Immunol Immunother"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"104908","DOI":"10.1016\/j.critrevonc.2025.104908","article-title":"Chemotherapy modulates PD-L1 expression and its combination with immune checkpoint blockade requires precision","volume":"214","author":"Zhang X","year":"2025","unstructured":"Zhang, X. et al. Chemotherapy modulates PD-L1 expression and its combination with immune checkpoint blockade requires precision. Crit Rev Oncol Hematol 214, 104908, doi:10.1016\/j.critrevonc.2025.104908 (2025).","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"850","DOI":"10.7150\/jca.81899","article-title":"Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy","volume":"14","author":"Zhang Y","year":"2023","unstructured":"Zhang, Y., Wu, J., Zhao, C., Zhang, S. & Zhu, J. Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy. J Cancer 14, 850\u2013873, doi:10.7150\/jca.81899 (2023).","journal-title":"J Cancer"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00428-018-2445-7","article-title":"Predictive potential and need for standardization of PD-L1 immunohistochemistry","volume":"474","author":"Savic Prince S","year":"2019","unstructured":"Savic Prince, S. & Bubendorf, L. Predictive potential and need for standardization of PD-L1 immunohistochemistry. Virchows Arch 474, 475\u2013484, doi:10.1007\/s00428-018-2445-7 (2019).","journal-title":"Virchows Arch"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"10215","DOI":"10.18632\/oncotarget.7143","article-title":"A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors","volume":"7","author":"Chatterjee S","year":"2016","unstructured":"Chatterjee, S. et al. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget 7, 10215\u201310227, doi:10.18632\/oncotarget.7143 (2016).","journal-title":"Oncotarget"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1021\/acs.bioconjchem.9b00178","article-title":"Noninvasive Imaging and Quantification of Radiotherapy-Induced PD-L1 Upregulation with (89)Zr-Df-Atezolizumab","volume":"30","author":"Ehlerding EB","year":"2019","unstructured":"Ehlerding, E. B. et al. Noninvasive Imaging and Quantification of Radiotherapy-Induced PD-L1 Upregulation with (89)Zr-Df-Atezolizumab. Bioconjug Chem 30, 1434\u20131441, doi:10.1021\/acs.bioconjchem.9b00178 (2019).","journal-title":"Bioconjug Chem"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"10239","DOI":"10.1002\/jcb.28308","article-title":"Near-infrared fluorescence-labeled anti-PD-L1-mAb for tumor imaging in human colorectal cancer xenografted mice","volume":"120","author":"Zhang M","year":"2019","unstructured":"Zhang, M. et al. Near-infrared fluorescence-labeled anti-PD-L1-mAb for tumor imaging in human colorectal cancer xenografted mice. J Cell Biochem 120, 10239\u201310247, doi:10.1002\/jcb.28308 (2019).","journal-title":"J Cell Biochem"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"E6506-6514","DOI":"10.1073\/pnas.1519623112","article-title":"Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging","volume":"112","author":"Maute RL","year":"2015","unstructured":"Maute, R. L. et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci U S A 112, E6506-6514, doi:10.1073\/pnas.1519623112 (2015).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013837","article-title":"PD-L1-targeted PET imaging for non-invasive assessment of immunotherapy response in lung cancer","volume":"14","author":"Chen Y","year":"2026","unstructured":"Chen, Y. et al. PD-L1-targeted PET imaging for non-invasive assessment of immunotherapy response in lung cancer. J Immunother Cancer 14, doi:10.1136\/jitc-2025-013837 (2026).","journal-title":"J Immunother Cancer"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1007\/s00259-023-06251-y","article-title":"Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in hepatocellular carcinoma","volume":"50","author":"Zhou X","year":"2023","unstructured":"Zhou, X. et al. Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 50, 3107\u20133115, doi:10.1007\/s00259-023-06251-y (2023).","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20210388","article-title":"Cumulative radiation doses from recurrent PET\u2013CT examinations","volume":"94","author":"Hosono M","year":"2021","unstructured":"Hosono, M. et al. Cumulative radiation doses from recurrent PET\u2013CT examinations. British Journal of Radiology 94, doi:10.1259\/bjr.20210388 (2021).","journal-title":"British Journal of Radiology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00247-009-1434-z","article-title":"Estimated cumulative radiation dose from PET\/CT in children with malignancies: a 5-year retrospective review","volume":"40","author":"Chawla SC","year":"2010","unstructured":"Chawla, S. C. et al. Estimated cumulative radiation dose from PET\/CT in children with malignancies: a 5-year retrospective review. Pediatr Radiol 40, 681\u2013686, doi:10.1007\/s00247-009-1434-z (2010).","journal-title":"Pediatr Radiol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"10877","DOI":"10.1039\/d4tb01148a","article-title":"Activatable near-infrared fluorescence probe for real-time imaging of PD-L1 expression in tumors","volume":"12","author":"Kim H","year":"2024","unstructured":"Kim, H. et al. Activatable near-infrared fluorescence probe for real-time imaging of PD-L1 expression in tumors. J Mater Chem B 12, 10877\u201310885, doi:10.1039\/d4tb01148a (2024).","journal-title":"J Mater Chem B"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1021\/acs.bioconjchem.4c00266","article-title":"AUNP-12 Near-Infrared Fluorescence Probes across NIR-I to NIR-II Enable In Vivo Detection of PD-1\/PD-L1 Axis in the Tumor Microenvironment","volume":"35","author":"Zhang X","year":"2024","unstructured":"Zhang, X., Wang, P., Shi, G., Tang, C. & Xue, H. AUNP-12 Near-Infrared Fluorescence Probes across NIR-I to NIR-II Enable In Vivo Detection of PD-1\/PD-L1 Axis in the Tumor Microenvironment. Bioconjugate Chemistry 35, 1064\u20131074, doi:10.1021\/acs.bioconjchem.4c00266 (2024).","journal-title":"Bioconjugate Chemistry"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1038\/s41467-023-40324-8","article-title":"EGFR-targeted fluorescence molecular imaging for intraoperative margin assessment in oral cancer patients: a phase II trial","volume":"14","author":"Wit JG","year":"2023","unstructured":"de Wit, J. G. et al. EGFR-targeted fluorescence molecular imaging for intraoperative margin assessment in oral cancer patients: a phase II trial. Nat Commun 14, 4952, doi:10.1038\/s41467-023-40324-8 (2023).","journal-title":"Nat Commun"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8282","author":"Tummers QR","year":"2016","unstructured":"Tummers, Q. R. et al. Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17. Oncotarget 7, 32144\u201332155, doi:10.18632\/oncotarget.8282 (2016)."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/pcmr.13159","article-title":"Molecular skin fluorescence imaging: A tool for evaluating early melanoma development","volume":"37","author":"Shachaf A","year":"2024","unstructured":"Shachaf, A., Manbeck, K., Yang, G. & Shachaf, C. Molecular skin fluorescence imaging: A tool for evaluating early melanoma development. Pigment Cell & Melanoma Research 37, 372\u2013377, doi:https:\/\/doi.org\/10.1111\/pcmr.13159 (2024).","journal-title":"Pigment Cell & Melanoma Research"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/nm729","article-title":"Fluorescence molecular tomography resolves protease activity in vivo","volume":"8","author":"Ntziachristos V","year":"2002","unstructured":"Ntziachristos, V., Tung, C.-H., Bremer, C. & Weissleder, R. Fluorescence molecular tomography resolves protease activity in vivo. Nature Medicine 8, 757\u2013761, doi:10.1038\/nm729 (2002).","journal-title":"Nature Medicine"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1158\/0008-5472.Can-14-3001","article-title":"In vivo tomographic imaging of deep-seated cancer using fluorescence lifetime contrast","volume":"75","author":"Rice WL","year":"2015","unstructured":"Rice, W. L., Shcherbakova, D. M., Verkhusha, V. V. & Kumar, A. T. In vivo tomographic imaging of deep-seated cancer using fluorescence lifetime contrast. Cancer Res 75, 1236\u20131243, doi:10.1158\/0008-5472.Can-14-3001 (2015).","journal-title":"Cancer Res"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"030509","DOI":"10.1117\/1.3149854","article-title":"In-vivo imaging of murine tumors using complete-angle projection fluorescence molecular tomography","volume":"14","author":"Deliolanis NC","year":"2009","unstructured":"Deliolanis, N. C. et al. In-vivo imaging of murine tumors using complete-angle projection fluorescence molecular tomography. J Biomed Opt 14, 030509, doi:10.1117\/1.3149854 (2009).","journal-title":"J Biomed Opt"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1364\/ol.35.003189","article-title":"Full-field time-resolved fluorescence tomography of small animals","volume":"35","author":"Venugopal V","year":"2010","unstructured":"Venugopal, V., Chen, J., Lesage, F. & Intes, X. Full-field time-resolved fluorescence tomography of small animals. Opt Lett 35, 3189\u20133191, doi:10.1364\/ol.35.003189 (2010).","journal-title":"Opt Lett"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/diagnostics14060585","article-title":"Current Trends and Applications of PET\/MRI Hybrid Imaging in Neurodegenerative Diseases and Normal Aging","author":"Lee J","year":"2024","unstructured":"Lee, J. et al. Current Trends and Applications of PET\/MRI Hybrid Imaging in Neurodegenerative Diseases and Normal Aging. Diagnostics (Basel) 14, doi:10.3390\/diagnostics14060585 (2024).","journal-title":"Diagnostics (Basel)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1117\/1.JBO.17.6.066001","article-title":"Improved tumor contrast achieved by single time point dual-reporter fluorescence imaging","volume":"17","author":"Tichauer KM","year":"2012","unstructured":"Tichauer, K. M. et al. Improved tumor contrast achieved by single time point dual-reporter fluorescence imaging. J Biomed Opt 17, 066001, doi:10.1117\/1.JBO.17.6.066001 (2012).","journal-title":"J Biomed Opt"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"938","DOI":"10.7150\/thno.37443","article-title":"Monoclonal antibody-based molecular imaging strategies and theranostic opportunities","volume":"10","author":"Dammes N","year":"2020","unstructured":"Dammes, N. & Peer, D. Monoclonal antibody-based molecular imaging strategies and theranostic opportunities. Theranostics 10, 938\u2013955, doi:10.7150\/thno.37443 (2020).","journal-title":"Theranostics"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1158\/1078-0432.Ccr-13-1826","article-title":"In vivo fluorescence lifetime imaging for monitoring the efficacy of the cancer treatment","volume":"20","author":"Ardeshirpour Y","year":"2014","unstructured":"Ardeshirpour, Y. et al. In vivo fluorescence lifetime imaging for monitoring the efficacy of the cancer treatment. Clin Cancer Res 20, 3531\u20133539, doi:10.1158\/1078-0432.Ccr-13-1826 (2014).","journal-title":"Clin Cancer Res"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"6653","DOI":"10.1158\/1078-0432.CCR-19-1686","article-title":"Fluorescence Lifetime-Based Tumor Contrast Enhancement Using an EGFR Antibody-Labeled Near-Infrared Fluorophore","volume":"25","author":"Pal R","year":"2019","unstructured":"Pal, R., Kang, H., Choi, H. S. & Kumar, A. T. N. Fluorescence Lifetime-Based Tumor Contrast Enhancement Using an EGFR Antibody-Labeled Near-Infrared Fluorophore. Clin Cancer Res 25, 6653\u20136661, doi:10.1158\/1078-0432.CCR-19-1686 (2019).","journal-title":"Clin Cancer Res"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41551-023-01105-2","article-title":"Fluorescence lifetime of injected indocyanine green as a universal marker of solid tumours in patients","volume":"7","author":"Pal R","year":"2023","unstructured":"Pal, R. et al. Fluorescence lifetime of injected indocyanine green as a universal marker of solid tumours in patients. Nat Biomed Eng 7, 1649\u20131666, doi:10.1038\/s41551-023-01105-2 (2023).","journal-title":"Nat Biomed Eng"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1158\/1078-0432.CCR-21-3429","article-title":"First Clinical Results of Fluorescence Lifetime-enhanced Tumor Imaging Using Receptor-targeted Fluorescent Probes","volume":"28","author":"Pal R","year":"2022","unstructured":"Pal, R. et al. First Clinical Results of Fluorescence Lifetime-enhanced Tumor Imaging Using Receptor-targeted Fluorescent Probes. Clin Cancer Res 28, 2373\u20132384, doi:10.1158\/1078-0432.CCR-21-3429 (2022).","journal-title":"Clin Cancer Res"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1021\/cr900343z","article-title":"Fluorescence lifetime measurements and biological imaging","volume":"110","author":"Berezin MY","year":"2010","unstructured":"Berezin, M. Y. & Achilefu, S. Fluorescence lifetime measurements and biological imaging. Chem Rev 110, 2641\u20132684, doi:10.1021\/cr900343z (2010).","journal-title":"Chem Rev"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1364\/BOE.459935","article-title":"N. Comparison of fluorescence lifetime and multispectral imaging for quantitative multiplexing in biological tissue","volume":"13","author":"Pal R","year":"2022","unstructured":"Pal, R. & Kumar, A. T. N. Comparison of fluorescence lifetime and multispectral imaging for quantitative multiplexing in biological tissue. Biomed Opt Express 13, 3854\u20133868, doi:10.1364\/BOE.459935 (2022).","journal-title":"Biomed Opt Express"},{"key":"ref48","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-46312-4","volume-title":"Principles of fluorescence spectroscopy","author":"Lakowicz JR","year":"2006","unstructured":"Lakowicz, J. R. Principles of fluorescence spectroscopy. (Springer, 2006)."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"40501","DOI":"10.1117\/1.JBO.22.4.040501","article-title":"Fluorescence lifetime-based contrast enhancement of indocyanine green-labeled tumors","volume":"22","author":"Kumar AT","year":"2017","unstructured":"Kumar, A. T. et al. Fluorescence lifetime-based contrast enhancement of indocyanine green-labeled tumors. J Biomed Opt 22, 40501, doi:10.1117\/1.JBO.22.4.040501 (2017).","journal-title":"J Biomed Opt"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"054003","DOI":"10.1117\/1.2070148","article-title":"Whole-body fluorescence lifetime imaging of a tumor-targeted near-infrared molecular probe in mice","volume":"10","author":"Bloch S","year":"2005","unstructured":"Bloch, S. et al. Whole-body fluorescence lifetime imaging of a tumor-targeted near-infrared molecular probe in mice. J Biomed Opt 10, 054003, doi:10.1117\/1.2070148 (2005).","journal-title":"J Biomed Opt"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1158\/0008-5472.CAN-24-0880","article-title":"Fluorescence Lifetime Imaging Enables In Vivo Quantification of PD-L1 Expression and Intertumoral Heterogeneity","volume":"85","author":"Pal R","year":"2025","unstructured":"Pal, R. et al. Fluorescence Lifetime Imaging Enables In Vivo Quantification of PD-L1 Expression and Intertumoral Heterogeneity. Cancer Res 85, 618\u2013632, doi:10.1158\/0008-5472.CAN-24-0880 (2025).","journal-title":"Cancer Res"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/759057","author":"Zhao P","year":"2013","unstructured":"Zhao, P. et al. Molecular imaging of hepatocellular carcinoma xenografts with epidermal growth factor receptor targeted affibody probes. Biomed Res Int 2013, 759057, doi:10.1155\/2013\/759057 (2013)."},{"key":"ref53","doi-asserted-by":"crossref","first-page":"046011-046011-046019","DOI":"10.1117\/1.3469797","article-title":"Lifetime-based tomographic multiplexing","volume":"15","author":"Raymond SB","year":"2010","unstructured":"Raymond, S. B., Boas, D. A., Bacskai, B. J. & Kumar, A. T. Lifetime-based tomographic multiplexing. Journal of biomedical optics 15, 046011-046011-046019 (2010).","journal-title":"Journal of biomedical optics"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"12255","DOI":"10.1364\/OE.14.012255","article-title":"Time resolved fluorescence tomography of turbid media based on lifetime contrast","volume":"14","author":"Kumar AT","year":"2006","unstructured":"Kumar, A. T., Raymond, S. B., Boverman, G., Boas, D. A. & Bacskai, B. J. Time resolved fluorescence tomography of turbid media based on lifetime contrast. Optics express 14, 12255\u201312270 (2006).","journal-title":"Optics express"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.7150\/thno.116640","article-title":"Use of Dual-Modality Antibody Imaging for Assessment of Lymph Node Metastases in Head and Neck Cancer","volume":"16","author":"Meeks N","year":"2026","unstructured":"Meeks, N. et al. Use of Dual-Modality Antibody Imaging for Assessment of Lymph Node Metastases in Head and Neck Cancer. Theranostics 16, 3946\u20133958, doi:10.7150\/thno.116640 (2026).","journal-title":"Theranostics"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"23472","DOI":"10.1021\/acs.jmedchem.5c02376","article-title":"A Comparative Study on the Effect of Near-Infrared Fluorescent Dyes on the Pharmacokinetic Behavior of Nanobody-Based Tracers for In Vivo Imaging","volume":"68","author":"Declerck NB","year":"2025","unstructured":"Declerck, N. B. et al. A Comparative Study on the Effect of Near-Infrared Fluorescent Dyes on the Pharmacokinetic Behavior of Nanobody-Based Tracers for In Vivo Imaging. J Med Chem 68, 23472\u201323484, doi:10.1021\/acs.jmedchem.5c02376 (2025).","journal-title":"J Med Chem"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1158\/1078-0432.Ccr-19-4156","article-title":"First-in-Human Assessment of cRGD-ZW800-1, a Zwitterionic, Integrin-Targeted, Near-Infrared Fluorescent Peptide in Colon Carcinoma","volume":"26","author":"Valk KS","year":"2020","unstructured":"de Valk, K. S. et al. First-in-Human Assessment of cRGD-ZW800-1, a Zwitterionic, Integrin-Targeted, Near-Infrared Fluorescent Peptide in Colon Carcinoma. Clinical Cancer Research 26, 3990\u20133998, doi:10.1158\/1078-0432.Ccr-19-4156 (2020).","journal-title":"Clinical Cancer Research"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"144881","DOI":"10.1016\/j.ijbiomac.2025.144881","article-title":"Transformative protein scaffold designs for dual-modality cancer applications: Advances in therapeutic delivery and molecular imaging of tumor microenvironments","volume":"318","author":"Alissa M","year":"2025","unstructured":"Alissa, M. et al. Transformative protein scaffold designs for dual-modality cancer applications: Advances in therapeutic delivery and molecular imaging of tumor microenvironments. Int J Biol Macromol 318, 144881, doi:10.1016\/j.ijbiomac.2025.144881 (2025).","journal-title":"Int J Biol Macromol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"R61","DOI":"10.1186\/bcr3167","article-title":"In vivo breast cancer characterization imaging using two monoclonal antibodies activatably labeled with near infrared fluorophores","volume":"14","author":"Sano K","year":"2012","unstructured":"Sano, K., Mitsunaga, M., Nakajima, T., Choyke, P. L. & Kobayashi, H. In vivo breast cancer characterization imaging using two monoclonal antibodies activatably labeled with near infrared fluorophores. Breast Cancer Research 14, R61 (2012).","journal-title":"Breast Cancer Research"},{"key":"ref60","first-page":"221","article-title":"High-dose, unlabeled, nonspecific antibody pretreatment: influence on specific antibody localization to human melanoma xenografts","volume":"24","author":"Wahl RL","year":"1987","unstructured":"Wahl, R. L., Wilson, B. S., Liebert, M. & Beierwaltes, W. H. High-dose, unlabeled, nonspecific antibody pretreatment: influence on specific antibody localization to human melanoma xenografts. Cancer Immunology, Immunotherapy 24, 221\u2013224 (1987).","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1139\/y93-018","article-title":"Hepatic blood flow distribution: consideration of gravity, liver surface, and norepinephrine on regional heterogeneity","volume":"71","author":"Lautt WW","year":"1993","unstructured":"Lautt, W. W., Schafer, J. & Legare, D. J. Hepatic blood flow distribution: consideration of gravity, liver surface, and norepinephrine on regional heterogeneity. Can J Physiol Pharmacol 71, 128\u2013135, doi:10.1139\/y93-018 (1993).","journal-title":"Can J Physiol Pharmacol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"020901","DOI":"10.1117\/1.JBO.27.2.020901","article-title":"Deep learning in macroscopic diffuse optical imaging","volume":"27","author":"Smith JT","year":"2022","unstructured":"Smith, J. T., Ochoa, M., Faulkner, D., Haskins, G. & Intes, X. Deep learning in macroscopic diffuse optical imaging. Journal of Biomedical Optics 27, 020901\u2013020901 (2022).","journal-title":"Journal of Biomedical Optics"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1912707116","author":"Smith JT","year":"2019","unstructured":"Smith, J. T. et al. Fast fit-free analysis of fluorescence lifetime imaging via deep learning. Proceedings of the National Academy of Sciences 116, 24019\u201324030, doi:doi:10.1073\/pnas.1912707116 (2019)."},{"key":"ref64","author":"Niedre MJ","year":"2008","unstructured":"Niedre, M. J. et al. Early photon tomography allows fluorescence detection of lung carcinomas and disease progression in mice in vivo. Proceedings of the National Academy of Sciences 105, 19126\u201319131 (2008)."},{"key":"ref65","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1364\/BOE.2.000871","article-title":"Monte Carlo based method for fluorescence tomographic imaging with lifetime multiplexing using time gates","volume":"2","author":"Chen J","year":"2011","unstructured":"Chen, J., Venugopal, V. & Intes, X. Monte Carlo based method for fluorescence tomographic imaging with lifetime multiplexing using time gates. Biomedical optics express 2, 871\u2013886 (2011).","journal-title":"Biomedical optics express"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nmeth.2014","article-title":"FMT-XCT: in vivo animal studies with hybrid fluorescence molecular tomography\u2013X-ray computed tomography","volume":"9","author":"Ale A","year":"2012","unstructured":"Ale, A. et al. FMT-XCT: in vivo animal studies with hybrid fluorescence molecular tomography\u2013X-ray computed tomography. Nature Methods 9, 615\u2013620, doi:10.1038\/nmeth.2014 (2012).","journal-title":"Nature Methods"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"e223-e231","DOI":"10.1016\/j.cllc.2025.01.008","article-title":"A Retrospective Evaluation of PD-L1 Expression and Heterogeneity in Early-Stage Non-Small Cell Lung Cancer (REPLICA)","volume":"26","author":"Josephides EC","year":"2025","unstructured":"Josephides, E. C. et al. A Retrospective Evaluation of PD-L1 Expression and Heterogeneity in Early-Stage Non-Small Cell Lung Cancer (REPLICA). Clin Lung Cancer 26, e223-e231, doi:10.1016\/j.cllc.2025.01.008 (2025).","journal-title":"Clin Lung Cancer"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"6453","DOI":"10.1158\/1078-0432.Ccr-20-2085","article-title":"Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy","volume":"26","author":"Zhou KI","year":"2020","unstructured":"Zhou, K. I. et al. Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy. Clinical Cancer Research 26, 6453\u20136463, doi:10.1158\/1078-0432.Ccr-20-2085 (2020).","journal-title":"Clinical Cancer Research"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.1364\/OE.15.006696","article-title":"Three-dimensional in vivo fluorescence diffuse optical tomography of breast cancer in humans","volume":"15","author":"Corlu A","year":"2007","unstructured":"Corlu, A. et al. Three-dimensional in vivo fluorescence diffuse optical tomography of breast cancer in humans. Optics express 15, 6696\u20136716 (2007).","journal-title":"Optics express"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1200\/jco.22.00291","article-title":"A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006)","volume":"41","author":"Tanyi JL","year":"2023","unstructured":"Tanyi, J. L. et al. A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006). J Clin Oncol 41, 276\u2013284, doi:10.1200\/jco.22.00291 (2023).","journal-title":"J Clin Oncol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10549-021-06106-w","article-title":"Performance of a novel protease-activated fluorescent imaging system for intraoperative detection of residual breast cancer during breast conserving surgery","volume":"187","author":"Lanahan CR","year":"2021","unstructured":"Lanahan, C. R. et al. Performance of a novel protease-activated fluorescent imaging system for intraoperative detection of residual breast cancer during breast conserving surgery. Breast Cancer Res Treat 187, 145\u2013153, doi:10.1007\/s10549-021-06106-w (2021).","journal-title":"Breast Cancer Res Treat"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9682833\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9682833\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:15:36Z","timestamp":1780496136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9682833\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":71,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9682833\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,6,3]]},"subtype":"preprint"}}